title: Determinants of rifabutin-associated uveitis in patients treated with rifabutin, clarithromycin, and ethambutol for Mycobacterium avium complex bacteremia: a multivariate analysis. Canadian HIV Trials Network Protocol 010 Study Group.
abstract: Uveitis occurred in a substantial proportion of AIDS patients receiving rifabutin, 600 mg daily, together with clarithromycin and ethambutol for treatment of Mycobacterium avium complex bacteremia. A case-control study was undertaken to examine potential risk factors for developing uveitis. Of eight parameters examined, only baseline body weight predicted the development of uveitis by both univariate and multivariate analyses (P = .001). The incidence of uveitis was 14% in patients weighing >65 kg, 45% in patients between 55 and 65 kg, and 64% in patients <55 kg. Concomitant therapy with fluconazole, a drug known to raise serum rifabutin concentrations, was not associated with an increased incidence of uveitis. The risk of uveitis was markedly reduced when rifabutin was given at 300 mg daily in combination with clarithromycin and ethambutol.
authors.affiliation: Department of Medicine, University of Alberta, Edmonton.
authors.forename: S D
authors.initials: SD
authors.lastname: Shafran
authors.forename: J
authors.initials: J
authors.lastname: Singer
authors.forename: D P
authors.initials: DP
authors.lastname: Zarowny
authors.forename: J
authors.initials: J
authors.lastname: Deschênes
authors.forename: P
authors.initials: P
authors.lastname: Phillips
authors.forename: F
authors.initials: F
authors.lastname: Turgeon
authors.forename: F Y
authors.initials: FY
authors.lastname: Aoki
authors.forename: E
authors.initials: E
authors.lastname: Toma
authors.forename: M
authors.initials: M
authors.lastname: Miller
authors.forename: R
authors.initials: R
authors.lastname: Duperval
authors.forename: C
authors.initials: C
authors.lastname: Lemieux
authors.forename: W F
authors.initials: WF
authors.lastname: Schlech
mesh_terms: D017088:AIDS-Related Opportunistic Infections / Q000188:drug therapy; D000328:Adult; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D000904:Antibiotics, Antitubercular / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D000995:Antitubercular Agents / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D016470:Bacteremia / Q000150:complications*; D017291:Clarithromycin / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D004977:Ethambutol / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D015994:Incidence; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D015270:Mycobacterium avium-intracellulare Infection / Q000188:drug therapy*; D017828:Rifabutin / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D012307:Risk Factors; D014605:Uveitis / Q000139:chemically induced*
chemical_list: D000900:Anti-Bacterial Agents; D000904:Antibiotics, Antitubercular; D000995:Antitubercular Agents; D017828:Rifabutin; D004977:Ethambutol; D017291:Clarithromycin